Skip to main content

Advertisement

SpringerLink
Log in

Antiretroviral drug resistance mutations in naïve and experienced patients in Shiraz, Iran, 2014

  • Original Article
  • Published:
Archives of Virology Aims and scope Submit manuscript

Abstract

Resistance to antiretroviral agents is a significant concern in the clinical management of HIV-infected individuals, particularly in areas of the world where treatment options are limited. In this study, we aimed to identify HIV drug-resistance-associated mutations in 40 drug-naïve patients and 62 patients under antiretroviral therapy (ART) referred to the Shiraz HIV/AIDS Research Center – the first such data available for the south of Iran. HIV reverse transcriptase and protease genes were amplified and sequenced to determine subtypes and antiretroviral- resistance-associated mutations (RAMs). Subtype CRF35-AD recombinant was the most prevalent in all patients (98 of 102, 96 %), followed by subtype A1, and subtype B (one each, 2 %). Among the 40 ART-naïve patients, two mutations associated with nucleoside reverse transcriptase inhibitor (NRTI) resistance (two with Y115F and T215I) and three associated with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance (two with G190S and Y181C, four with V179T) were found. Among ART-experienced patients, four mutations associated with resistance to NRTI, four with NNRTI, and five with protease inhibitors (PI) were found. Twenty patients with high levels of resistance were already on second-line therapy. We document for the first time in this region of Iran high levels of ART resistance to multiple drugs. Our findings call for more vigilant systematic ART resistance surveillance, increased resistance testing, careful management of patients with existing regimens, and strong advocacy for expansion of available drugs in Iran.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Clavel F, Hance AJ (2004) HIV drug resistance. N Engl J Med 350(10):1023–1035

    Article  CAS  PubMed  Google Scholar 

  2. Cortez KJ, Maldarelli F (2011) Clinical management of HIV drug resistance. Viruses 3(4):347–378

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF et al (2004) The prevalence of antiretroviral drug resistance in the United States. Aids 18(10):1393–1401

    Article  PubMed  Google Scholar 

  4. Thomson MM, Pérez-Álvarez L, Nájera R (2002) Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2(8):461–471

    Article  CAS  Google Scholar 

  5. Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F et al (2002) Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1—positive persons in Uganda. J Infect Dis 185(9):1244–1250

    Article  PubMed  Google Scholar 

  6. Alaeus A, Lidman K, Björkman A, Giesecke J, Albert J (1999) Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes AD. Aids 13(8):901–907

    Article  CAS  PubMed  Google Scholar 

  7. Pieniazek D, Rayfield M, Hu DJ, Nkengasong J, Wiktor SZ, Downing R et al (2000) Protease sequences from HIV-1 group M subtypes A–H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. Aids 14(11):1489–1495

    Article  CAS  PubMed  Google Scholar 

  8. Frater AJ, Dunn DT, Beardall AJ, Ariyoshi K, Clarke JR, McClure MO et al (2002) Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. Aids 16(8):1139–1146

    Article  CAS  PubMed  Google Scholar 

  9. Pennings PS (2012) HIV drug resistance: problems and perspectives. arXiv preprint arXiv:12115807

  10. Frentz D, Boucher C, Van De Vijver D (2012) Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDs Rev 14(1):17–27

    PubMed  Google Scholar 

  11. Baesi K, Ravanshad M, Ghanbarisafari M, Saberfar E, SeyedAlinaghi S, Volk JE (2014) Antiretroviral drug resistance among antiretroviral-naïve and treatment experienced patients infected with HIV in Iran. J Med Virol 86(7):1093–1098

    Article  CAS  PubMed  Google Scholar 

  12. Jahanbakhsh F, Hattori J, Matsuda M, Ibe S, Monavari S-HR, Memarnejadian A et al (2013) Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011. PloS One 8(4):e61864

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Mousavi SM, Hamkar R, Gouya MM, Safaie A, Zahraei SM, Yazdani Z et al (2010) Surveillance of HIV drug resistance transmission in Iran: experience gained from a pilot study. Arch Virol 155(3):329–334

    Article  CAS  PubMed  Google Scholar 

  14. Baesi K, Moallemi S, Farrokhi M, Alinaghi SAS, Truong HHM (2014) Subtype classification of Iranian HIV-1 sequences registered in the HIV databases, 2006–2013. PloS One 9(9):e105098

    Article  PubMed  PubMed Central  Google Scholar 

  15. Stuyver L (1999) Method for detection of drug-selected mutations in the HIV protease gene. Google Patents

  16. Edelstein RE, Nickerson DA, Tobe VO, Manns-Arcuino LA, Frenkel LM (1998) Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 polGene that are associated with resistance to zidovudine, didanosine, and lamivudine. J Clin Microbiol 36(2):569–572

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Rhee S-Y, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW (2003) Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31(1):298–303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Sarrami-Forooshani R, Das SR, Sabahi F, Adeli A, Esmaeili R, Wahren B et al (2006) Molecular analysis and phylogenetic characterization of HIV in Iran. J Med Virol 78(7):853–863

    Article  CAS  PubMed  Google Scholar 

  19. Hamkar R, Mohraz M, Lorestani S, Aghakhani A, Truong H-HM, McFarland W et al (2010) Assessing subtype and drug-resistance-associated mutations among antiretroviral-treated HIV-infected patients. Aids 24:S85–S91

    Article  PubMed  Google Scholar 

  20. Soheilli ZS, Ataiee Z, Tootian S, Zadsar M, Amini S, Abadi K et al (2009) Presence of HIV-1 CRF35_AD in Iran. AIDS Res Hum Retrovir 25(1):123–125

    Article  PubMed  Google Scholar 

  21. Baesi k, Moradbeigi M, Ravanshad M, Baghban A (2016) Phylogeny and drug resistance of HIV PR gene among HIV patients receiving RT inhibitors in Iran. Asian Pac J Trop Biomed. doi:10.1016/j.apjtb.2015.12.020

  22. Gholami M, Sadeghi L, Baesi K, Rouzbahani NH, Mohraz M (2015) Survey of antiretroviral drug resistance pattern among HIV-infected patients with treatment failure in Iran. J Hum Virol Retrovir 3(1):1–6

  23. Memarnejadian A, Menbari S, Mansouri SA, Sadeghi L, Vahabpour R, Aghasadeghi MR et al (2015) Transmitted drug resistance mutations in antiretroviral-naïve injection drug users with chronic HIV-1 infection in Iran. PloS One 10(5):e0126955

    Article  PubMed  PubMed Central  Google Scholar 

  24. Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H et al (2001) Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 134(6):440–450

    Article  CAS  PubMed  Google Scholar 

  25. Smith D, Moini N, Pesano R, Cachay E, Aiem H, Lie Y et al (2007) Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. Clin Infect Dis 44(3):456–458

    Article  PubMed  Google Scholar 

  26. World Health Organization (2012) The HIV drug resistance report-2012. World Health Organization, Geneva

  27. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, Hampton J et al (2008) Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 46(10):1589–1597

    Article  PubMed  PubMed Central  Google Scholar 

  28. Baesi K, Ravanshad M, Hosseini Y, Abdolbaghi MH (2012) Drug resistance profile and subtyping of HIV-1 RT gene in Iranian patients under treatment. Iran J Biotechnol 10(1)

  29. Lee N, Hogg RS, Yip B, Harrigan PR, Harris M, O’Shaughnessy MV et al (2003) Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy. J Infect Dis 188(1):137–141

    Article  PubMed  Google Scholar 

  30. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P et al (1995) Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 171(6):1411–1419

    Article  CAS  PubMed  Google Scholar 

  31. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P et al (1999) Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomised controlled trial. Lancet 353(9171):2195–2199

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

The authors would like to acknowledge Golestan University of Medical Sciences for financial support.

Author information

Authors and Affiliations

  1. Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

    Hamed Naziri

  2. Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Falsafi Educational Campus, Shaskalate, 5th km Gorgan, Tehran Rd., Gorgan, Iran

    Hamed Naziri, Abdolvahab Moradi & Alijan Tabarraei

  3. Department of Hepatitis and AIDS, Pasteur Institute of Iran, Pasteur Ave., Tehran, 1316943551, Iran

    Kazem Baesi & Mohammad R. Aghasadeghi

  4. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA

    Willi McFarland

  5. Shiraz HIV and AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    Mohamad Ali Davarpanah

Authors
  1. Hamed Naziri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazem Baesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abdolvahab Moradi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammad R. Aghasadeghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alijan Tabarraei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Willi McFarland
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mohamad Ali Davarpanah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Kazem Baesi or Abdolvahab Moradi.

Ethics declarations

Funding source

Golestan University of Medical Sciences.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Naziri, H., Baesi, K., Moradi, A. et al. Antiretroviral drug resistance mutations in naïve and experienced patients in Shiraz, Iran, 2014. Arch Virol 161, 2503–2509 (2016). https://doi.org/10.1007/s00705-016-2955-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00705-016-2955-z

Keywords

Search

Navigation